Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance

Léa Montégut; Isabelle Martins; Guido Kroemer

doi:10.1080/2162402X.2024.2413200

Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance

Oncoimmunology. 2024 Oct 7;13(1):2413200. doi: 10.1080/2162402X.2024.2413200. eCollection 2024.

Authors

Léa Montégut^{1

2}, Isabelle Martins^{1

2}, Guido Kroemer^{1

3}

Affiliations

¹ Team Metabolism, Cancer and Immunity, Centre de Recherche des Cordeliers, INSERM U1138, Équipe Labellisée - Ligue Nationale contre le Cancer, Université Paris Cité, Sorbonne Université, Paris, France.
² Team Metabolism, Cancer and Immunity, Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
³ Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Abstract

Acyl CoA binding protein (ACBP) encoded by DBI is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in Molecular Cancer that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.

Keywords: Caloric restriction mimetics; chemotherapy; immune checkpoint inhibitor; immunotherapy mammary carcinoma; non-small cell lung cancer.

MeSH terms

Animals
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Autophagy* / drug effects
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunologic Surveillance / drug effects
Neoplasms* / drug therapy
Neoplasms* / immunology
Neoplasms* / metabolism
Neoplasms* / pathology

Substances

Antibodies, Monoclonal
Immune Checkpoint Inhibitors

Grants and funding

The work was supported by the Agence Nationale de la Recherche European Research Council Fondation pour la Recherche Médicale HORIZON EUROPE Framework Programme Institut National Du Cancer Institut Universitaire de France Ligue Contre le Cancer Hevolution Foundation Seerave Foundation.